Mechanisms of Signal Transduction
The Human Frizzled 6 (HFz6) Acts as a Negative Regulator of the Canonical Wnt·β-Catenin Signaling Cascade*

https://doi.org/10.1074/jbc.M306421200Get rights and content
Under a Creative Commons license
open access

Previously we have cloned the human Frizzled 1 (HFz1) and shown that it transmits the Wnt-3a-induced canonical pathway. We also cloned the human Frizzled 6 (HFz6) and show in the present study that, as opposed to HFz1, HFz6 did not activate the canonical Wnt pathway following exposure to various Wnts, whether belonging to the Wnt-1 or to the Wnt-5a group. Moreover we show that HFz6 repressed Wnt-3a-induced canonical signaling when co-expressed with HFz1. HFz6 repressed the canonical Wnt cascade activated also by various Wnt signaling intracellular mediators such as Dishevelled-1, a stabilized β-catenin(S33Y) mutant, and LiCl-mediated repression of glycogen synthase kinase-3β activity. Removal of HFz6 N′- or C′-terminal sequences abolished HFz6 repressive activity. As the HFz6 repressive effect was not associated with a decrease in the level of β-catenin, it is suggested that HFz6 does not affect β-catenin stabilization, implying that HFz6 transmits a repressive signaling that cross-talks with and inhibits the canonical Wnt pathway downstream of β-catenin destruction complex. HFz6 did not affect the level of nuclear T-cell factor 4 (TCF4) nor did it affect β-catenin·TCF4 complex formation. However, electrophoretic mobility shift assays indicated that HFz6 repressed the binding of TCF/lymphoid enhancer factor transcription factors to target DNA. Moreover we present data suggesting that HFz6 activates the transforming growth factor-β-activated kinase-NEMO-like kinase pathway that blocks TCF/lymphoid enhancer factor binding to target promoters, thereby inhibiting the ability of β-catenin to activate transcription of Wnt target genes.

Cited by (0)

*

This work was supported by grants from the United States-Israel Binational Science Foundation (BSF), Association for International Cancer Research (AICR), Israel Science Foundation founded by The Israel Academy of Science and Humanities, Israel Ministry of Health, Reccanati Fund for Medical Research, and Tel Aviv University Research Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

This work is in partial fulfillment of the requirements for the Ph.D. degree from the Sackler School of Medicine at Tel Aviv University.